Angiotech announces positive results from Bio-Seal(TM) clinical study

12-Mar-2009 - Angiotech Pharmaceuticals, Inc. announced positive clinical study results for its Bio-Seal(TM) Lung Biopsy Tract Plug System at the Society of Interventional Radiologists Annual Scientific Meeting in San Diego, CA. The trial assessed the safety and efficacy of Bio-Seal in patients undergoing lung ...

Novozymes Biopharma Signs License Agreement with GE Healthcare to Produce and Sell Protein A

11-Mar-2009 - Novozymes Biopharma UK Ltd., part of Novozymes, announced a newly signed license agreement with GE Healthcare Life Sciences. This license enables Novozymes Biopharma to produce and deliver native, animal-free protein A using GE Healthcare technology. Novozymes Biopharma's protein A, which is now ...

DSM and ROQUETTE to commercialize bio-based succinic acid as of end 2009

11-Mar-2009 - Royal DSM N.V. and ROQUETTE confirmed that its bio-based succinic acid demonstration plant in Lestrem (France) will be operational by the end of 2009. The pilot scale production has proven that this biological route for producing succinic acid can be commercially viable. The first tests for ...

ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema

09-Mar-2009 - ThromboGenics NV announced that it has completed patient enrolment for a Phase II trial of microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME). This trial is designed as the initial step in evaluating the utility of microplasmin in patients with ...

Novexel’s NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial

04-Mar-2009 - Novexe announced that its most advanced injectable antibacterial, which combines Novexel’s broad spectrum beta-lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered a second Phase II clinical trial. This Phase II trial with NXL104/ceftazidime ...

Crucell's Revolutionary Antibody for Universal Therapy Against Flu

03-Mar-2009 - Crucell N.V. announced that the journal Science published a study showing why Crucell's novel anti-influenza antibody is so effective against such a broad range of influenza virus subtypes. These characteristics make the Crucell antibody CR6261 a potentially revolutionary therapy against seasonal ...

DeveloGen Reports Positive Phase 1 Clinical Trial Results for DG3173

02-Mar-2009 - DeveloGen AG reported positive results from a Phase 1 study for DG3173, a novel somatostatin analogue. The results of the study indicate that DG3173 has an excellent safety and tolerability profile at all doses administered. The Phase 1 trial was designed as a randomized, double-blind, placebo ...

Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects

Phase II trials on both projects to be initiated during 2009

02-Mar-2009 - Archimedes Pharma Limited announced positive headline data from its recently completed proof-of-concept trials for two of its intranasal (IN) development projects. Both the IN Apomorphine and IN Diazepam Phase I studies showed high bioavailability, positive pharmacokinetics and good tolerability ...

Hawaii Biotech Inc reports favourable phase 1 interim results to treat West Nile Virus

27-Feb-2009 - Hawaii Biotech, Inc., announced successful Phase 1 clinical trial results of its West Nile Virus vaccine in healthy volunteers. Hawaii Biotech is developing a West Nile recombinant sub-unit vaccine to induce protective immunity in recipients of the vaccine. The results demonstrated a ...

ESBATech's Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study

New Clinical Advisory Board Established to Provide Industry Leadership and Ophthalmology Experience

26-Feb-2009 - ESBATech AG announced the initiation of a Phase IIa study in patients with acute anterior uveitis. This study is designed to evaluate the safety, tolerability, and clinical activity of topically applied ESBA105 in uveitis patients. ESBA105 is a single-chain antibody fragment directed against ...